Chokri Ben Lamine/LinkedIn
Jun 12, 2026, 16:14
Chokri Ben Lamine: EHA26 – SCD Curative Therapy Pathway
Chokri Ben Lamine, Assistant Consultant at King Faisal Specialist Hospital and Research Center, shared a post on X:
“EHA26 – SCD Curative Therapy Pathway
EHA-SWG and EBMT-HWP joint recommendations highlight who should be considered for:
- Allogeneic HCT
- Cell and gene therapy
in sickle cell disease
Key clinical logic:
- Confirm HbSS and severe HbSβ⁰ genotype
- Assess for severe clinical presentation
- If HLA-matched family donor is available, proceed to allo-HCT assessment
- If no matched donor is available and eligibility criteria are met, assess for gene therapy at a transplant center.
Practical message:
Curative therapy in SCD is becoming algorithm-driven, but still needs expert individualized review:
- genotype
- disease severity
- donor availability
- age
- regulatory and scientific updates
- patient-centered risk–benefit discussion
Session: Optimising the transplant process in haemoglobinopathies
Chair: Ben Carpenter”
Other posts featuring Chokri Ben Lamine on Hemostasis Today.
-
Jul 13, 2026, 20:17Julia R. Coleman: Fantastic First Day at ISTH 2026
-
Jul 13, 2026, 20:11Ruah Alyamany: Combination Therapy Improves Quality of Life in ITP
-
Jul 13, 2026, 19:47Brian O Mahony: Two-Year Results of BBM-H901 Gene Therapy Presented at ISTH 2026
-
Jul 13, 2026, 19:37Sara Zalghout: Connecting With Colleagues From All Over the World at ISTH 2026
-
Jul 13, 2026, 18:54Alfonso J. Tafur: New Evidence on Perioperative Anticoagulation in Cancer at ISTH 2026
-
Jul 13, 2026, 18:42Jessica Garcia: Thrombin Generation in Type 3 VWD With an Inhibitor on Emicizumab
-
Jul 13, 2026, 18:19Fionnuala Ní Áinle: High-Quality Evidence for DVT Diagnosis in Pregnancy at ISTH 2026
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026